Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Overman

Showing results (171-180 of 265) with videos related to

Pageof 27
Sort By:
Annals of Surgical Oncology|November 12, 2025
Clinicopathologic and Molecular Characteristics of High-Grade Appendiceal Mucinous NeoplasmsAshlee N Seldomridge, Michael G White, Christopher Scally, et al.
Biorxiv : the Preprint Server for Biology|April 17, 2026
KRAS inhibition is an effective therapy for appendiceal adenocarcinomaSaikat Chowdhury, Ichiaki Ito, Vinay K Pattalachinti, et al.
Clinical Colorectal Cancer|February 4, 2020
Patient-reported Symptom Outcomes and Microsatellite Instability in Patients With Metastatic Colorectal CancerShailesh M Advani, Quilling Shi, Michael J Overman, et al.
European Journal of Cancer (Oxford, England : 1990)|December 21, 2021
Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancerGiovanni Randon, Rossana Intini, Chiara Cremolini, et al.
Journal for Immunotherapy of Cancer|January 2, 2023
Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancerVincenzo Nasca, Francesco Barretta, Francesca Corti, et al.
Molecular Cancer Therapeutics|October 5, 2013
Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutationsPrasanth Ganesan, Filip Janku, Aung Naing, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 10, 2020
JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusionsT Yoshino, G Pentheroudakis, S Mishima, et al.
Annals of Surgical Oncology|October 23, 2023
Repeat Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Appendiceal Adenocarcinoma: A Viable Treatment Strategy with Demonstrable BenefitNeal Bhutiani, Travis E Grotz, Seth J Concors, et al.
Oncotarget|August 20, 2016
Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentinMichael J Overman, Van Morris, Helen Moinova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2021
Development and Validation of a Novel Nomogram for Individualized Prediction of Survival in Cancer of Unknown PrimaryKanwal Raghav, Hyunsoo Hwang, Alexandre A Jácome, et al.
Pageof 27

Showing results (171-180 of 265) with videos related to

Sort By:
Pageof 27
Annals of Surgical Oncology|November 12, 2025
Clinicopathologic and Molecular Characteristics of High-Grade Appendiceal Mucinous NeoplasmsAshlee N Seldomridge, Michael G White, Christopher Scally, et al.
Biorxiv : the Preprint Server for Biology|April 17, 2026
KRAS inhibition is an effective therapy for appendiceal adenocarcinomaSaikat Chowdhury, Ichiaki Ito, Vinay K Pattalachinti, et al.
Clinical Colorectal Cancer|February 4, 2020
Patient-reported Symptom Outcomes and Microsatellite Instability in Patients With Metastatic Colorectal CancerShailesh M Advani, Quilling Shi, Michael J Overman, et al.
European Journal of Cancer (Oxford, England : 1990)|December 21, 2021
Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancerGiovanni Randon, Rossana Intini, Chiara Cremolini, et al.
Journal for Immunotherapy of Cancer|January 2, 2023
Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancerVincenzo Nasca, Francesco Barretta, Francesca Corti, et al.
Molecular Cancer Therapeutics|October 5, 2013
Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutationsPrasanth Ganesan, Filip Janku, Aung Naing, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 10, 2020
JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusionsT Yoshino, G Pentheroudakis, S Mishima, et al.
Annals of Surgical Oncology|October 23, 2023
Repeat Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Appendiceal Adenocarcinoma: A Viable Treatment Strategy with Demonstrable BenefitNeal Bhutiani, Travis E Grotz, Seth J Concors, et al.
Oncotarget|August 20, 2016
Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentinMichael J Overman, Van Morris, Helen Moinova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2021
Development and Validation of a Novel Nomogram for Individualized Prediction of Survival in Cancer of Unknown PrimaryKanwal Raghav, Hyunsoo Hwang, Alexandre A Jácome, et al.
Pageof 27